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OBJECTIVES: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and
response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological
referral centre in northeastern Brazil.
METHODS: This was a retrospective cohort study of 36 patients diagnosed with MDS and treated with EPO alfa
at 30,000 to 60,000 IU per week. Clinical data were collected from medical records. The events assessed were
non-response to treatment and progression to acute myeloid leukaemia (AML). Statistical analyses were
performed using GraphPad Prism 7 and SPSS 24 software.
RESULTS: The overall survival of patients who received EPO alfa treatment was 51.64%, with a median of
65 months of treatment, and the overall survival of this group was 100% during the first 24 months. We
detected a 43.5-month median event-free survival, with a response rate of 80.5%. We observed responses from
25 to 175 months. Patients with transfusion dependence and those with a high-risk stratification, as determined
by the International Prognostic Scoring System (IPSS), the Revised International Prognostic Scoring System (IPSS-
R), the WHO classification-based Prognostic Scoring System (WPSS) and the WHO 2016, had a lower event-free
survival than other patients.
CONCLUSIONS: Despite the wide use of EPO alfa in the treatment of anaemia in patients with MDS, the median
response duration is approximately only 24 months. Our data provide encouraging results concerning the
benefits of using EPO alfa for the improvement of the quality of life, as patients treated with EPO showed
higher overall survival, event-free survival rates and longer response durations than have been previously
described in the literature.
KEYWORDS: Myelodysplastic Syndrome; Recombinant Human Erythropoietin; Erythropoietin; Epoetin Alfa;
EPO; EPO Alfa.
’ INTRODUCTION
Myelodysplastic syndrome (MDS) is a clonal haemato-
poietic disease characterized by ineffective haematopoiesis,
dysplasias, peripheral cytopenias, and the risk of transfor-
mation into acute myeloid leukaemia (AML) (1). Approxi-
mately 60% of patients with MDS have severe anaemia at
diagnosis, and this finding has been frequently associated
with an impaired quality of life, reduced motor and cognitive
functions, low haemoglobin concentrations, and transfusion
dependence (2).
Erythropoiesis-stimulating agents (ESAs), such as recom-
binant human erythropoietin (EPO), have been used to treat
anaemia in patients with MDS; ESAs constitute an important
therapeutic alternative since they reduce transfusion require-
ments and the risks associated with transfusions (3). Several
studies have shown a greater overall survival of MDS pati-
ents treated with ESAs than untreated anaemic patients (4,5),
and ESAs have been demonstrated to be efficacious and to
have a safety profile characterized by few adverse events (6).
Different isoforms of EPO are available; these isoforms differ
in their structure and response strength (7,8).
The refractoriness rate for ESAs is approximately 40-50%
after 2 years of treatment (4). The effectiveness of ESA treat-
ment seems to be associated with some clinical character-
istics, such as low serum EPO levels (o500 IU/L), a lack of
transfusion dependence, and a low-risk stratification based
on the Revised International Prognostic Scoring SystemDOI: 10.6061/clinics/2019/e771
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(IPSS-R) (3,9,10,11). However, the mechanisms that drive this
refractoriness have not been clarified.
Thus, the aim of the present study was to evaluate the
effects of epoetin (EPO) alfa treatment on the event-free
survival and response duration of patients with MDS who
were treated at a haematological referral centre in north-
eastern Brazil.
’ MATERIALS AND METHODS
This was a retrospective cohort study of 36 adult patients
of both genders who were diagnosed with MDS and treated
with EPO alfa. Follow-up occurred at the Haematology
Department of the Hospital Universitário Walter Cantídeo
(HUWC), Ceará, Brazil.
MDS was diagnosed according to the minimum criteria
established at the Vienna Conference on MDS in 2006 (12).
Patients were stratified according to their risk of progression
to AML, according to the criteria of the World Health
Organization 2016 (WHO 2016), the International Prognostic
Scoring System (IPSS), the IPSS-R, and the WHO Classifica-
tion-based Prognostic Scoring System (WPSS).
The response to treatment with EPO alfa was assessed
according to the criteria established by the International
Working Group (IWG) in 2006. The IWG defines a response
as an increase in haemoglobin levels of 1.5 g/dL or a reduc-
tion in the transfusion requirement of four units after every
8 weeks of treatment (13).
Clinical data related to age, sex, blood count, treatment
time, EPO alfa dose, transfusion dependence, myelogram,
bone biopsy, and karyotype were collected from medical
records.
Of the 42 patients treated with EPO alfa, six patients
(14.3%) who did not have medical records available before
treatment (which precluded any analysis of the evolution of
the response) were excluded from the study.
Statistical analyses were performed using GraphPad
Prism software version 7.0 and SPSS software version 24.
The results are expressed as the mean ± standard error of
the mean (SEM). A bivariate analysis was performed using
the chi-square test, and the global survival and event-free
survival analyses were performed using Kaplan-Meier
curves. The events considered for the analysis were non-
response to EPO alfa treatment and progression to AML.
Values of po0.05 were considered statistically significant.
’ RESULTS
The study population had a median age of 75 years (49-95
years) and had a predominance of females (55.55% female
and 44.45% male). Most patients were classified as low/very
low risk according to the IPSS-R (72.2%) and the WPSS
(83.3%). Based on the WHO classification, the majority of
patients were classified as MDS with multilineage dysplasia
(MDS-MLD) (38.9%), followed by MDS with ringed side-
roblasts (MDS-RS) (22.2%), MDS with dysplasia (MDS-SLD)
(13.9%), MDS with excess blasts -1,2 (MDS-EB-1,2) (8.3%),
and MDS with del (5q) isolated (11.1%); additionally, two
patients (5.6%) progressed to AML (Table 1).
The median follow-up was 50 months, ranging from
2 to 175 months. The overall survival of patients who had
a sustained response to EPO alfa treatment was 51.64%,
with a median of 65 months of treatment. During the first
24 months, the overall survival of this group was 100%.
For the group of patients who were refractory to EPO alfa
treatment, the overall survival was 14.28%, with a median of
3 months, which was significantly lower than the survival of
the group who responded to EPO alfa (po0.0001) (Figure 1).
Event-free survival throughout the follow-up period
was 80.5% (Figure 2A and Table 1). Haemoglobin values
increased significantly after 24 months and up to 175 months
after the initiation of EPO alfa treatment, and the haemoglo-
bin values remained higher than the values at the initiation
of treatment (po0.001) (Figure 3).
Patients with transfusion dependence (po0.0001), those
classified as high risk based on the IPSS (po0.0001) and
those classified as high/very high based on the IPSS-R
(po0.0001) and the WPSS (p=0.0005) had lower event-free
survival (Figure 2B-2E) than the other patients.
The WHO classification was also able to stratify groups
based on the response to treatment with EPO alfa. Event-free
survival rates were lower in patients classified as MDS-RS,
MDS-EB and del 5q than in patients classified as MDS-SLD
and MDS-MLD (p=0.03) (Figure 2F).
After up to 175 months of treatment with EPO alfa, the
event-free survival rates were greater than 93.3% in patients
with a low/very low-risk stratification and no transfusion
dependency (Figure 2B-2E).
A significant association was observed among the chi-
square test for karyotype (very poor, poor, intermediate, and
good, p=0.0015); normal, complex, trisomy, with del 5q and
monosomy (p=0.0205); and the response to EPO alfa treat-
ment (yes, no) (Table 1).
The main findings from the cytogenetic analysis showed
normal karyotypes in 77.77% (28/36) of patients. Patients
with a normal karyotype showed an 89.3% (25/28) res-
ponse to EPO alfa treatment; in contrast, there was a 50%
(4/8) response rate in patients with an altered karyotype.
Only 10.75% (3/28) of the patients with a normal karyotype
did not respond to treatment with EPO alfa. None of the
patients with a normal karyotype were transfusion depen-
dent (Table 1).
Patients with a good karyotype were more common
(88.9%, 32/36) than patients in the other cytogenetic risk
groups of the IPSS-R. Only 15.6% of the patients with a good
karyotype (5/32) were transfusion dependent, and 60% (3/5)
of these patients did not respond to EPO alfa. Seventy-five
percent of the patients with a 5q deletion responded to
treatment (Table 1).
The poor and very poor cytogenetic risk groups (5.55%,
2/36), which corresponded to complex karyotypes, did not
respond to EPO alfa (0%). The intermediate risk group (5.55%,
2/36) included one patient with a transfusion-dependent
trisomy of chromosome 8, who also did not respond to EPO
alfa treatment, and one patient with a monosomy of chro-
mosome 18, who showed a non-transfusion-dependent res-
ponse to treatment.
Only 33.33% (12/36) of patients had serum erythropoietin
(sEPO) level data available in their medical records: 16.66%
had sEPO levels 4200 mU/mL, and 83.33% had levels
o200 mU/mL. Patients who had elevated sEPO levels did
not respond to treatment (100%). Most of the patients with
sEPO levels o500 mU/mL (83.3%, 10/12) showed a
response to EPO alfa. None of the patients had serum
erythropoietin values 4500 mU/mL (Table 1).
Most patients (91.66%, 33/36) started with low doses
(30,000 IU) of EPO alfa that were administered weekly,
and most patients showed a positive response to treatment
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Table 1 - Response to EPO alfa treatment according to the clinical-laboratory characteristics of the study population (n=36).
Variable Subgroup Response X2* (p value)
Yes No
n/n total (%) n/n total (%)
29 / 36 (80.5%) 7/ 36 (19.44%)
SOCIO-DEMOGRAPHIC VARIABLES
Gender Female 16 / 20 (80%) 4 / 20 (20%) 1
Male 13 / 16 (81.2%) 3 / 16 (18.8%)
Age o75 11 / 15 (73.3%) 4 / 15 (26.7%) 0.4178
X75 18 / 21 (85.7%) 3 / 21 (14.3%)
p60 1 / 1 (100%) 0 / 1 (0%) 0.6502
460 - 75 13 / 17 (76.5%) 4 / 17 (23.5%)
475 - 90 13 / 16 (81.2%) 3 / 16 (18.8%)
490 2 / 2 (100%) 0 / 2 (0%)
BONE MARROW FINDINGS
Cellularity of the bone marrow Hypocellular 6 / 9 (66.7%) 3 / 9 (33.3%) 0.1855
Normocellular 9 / 9 (100%) 0 / 9 (0%)
Hypercellular 14 / 18 (77.8%) 4 / 18 (22.2%)
Ring sideroblasts Presence 21 / 24 (87.5%) 4 / 24 (16.7%) 0.3945
Absence 8 / 12 (66.7%) 4 / 12 (33.3%)
% Bone marrow blast p2% 25 / 26 (96.1%) 1 / 26 (3.9%) o0.0001
42% - o5% 3 / 4 (75%) 1 / 4 (25%)
5% - 10% 1 / 3 (33.3%) 2 / 3 (66.7%)
410% 0 / 3 (0%) 3 / 3 (100%)
PERIPHERAL BLOOD FINDINGS
Haemoglobin IPSS-R (g/dL)* X10 11 / 12 (91.7%) 1 / 12 (8.3)
8 - 10 11 /13 (84.6%) 2 / 13 (15.4%) 0.0922
o8 7 / 11 (63.6%) 4 / 11 (36.4%)
ANC IPSS-R= o0.8 6 / 7 (85.7%) 1 / 7 (14.3%) 1
X0.8 23 / 29 (79.3%) 6 / 29 (20.7%)
Platelets IPSS-Rw X50 2 / 4 (50%) 2 / 4 (50%)
450 - 100 1 / 3 (33.3%) 2 / 3 (66.7%) 0.0136
4100 26 / 29 (89.7%) 3 / 29 (10.3%)
Cytopeniasy 0 - 1 16 / 17 (94.1%) 1 / 17 (5.9%) 0.0918
2 - 3 13 / 19 (68.4%) 6 / 19 (31.6%)
CYTOGENETIC CHARACTERIZATION AND PROGNOSTIC IMPACT
Karyotype category 1 Normal 25 / 28 (89.3%) 3 / 28 (10.7%) 0.0301
Changed 4 / 8 (50%) 4 / 8 (50%)
Karyotype IPSS-R Very poor 0 / 1 (0%) 1 / 1 (100%)
Poor 0 / 1 (0%) 1 / 1 (100%) 0.0015
Intermediary 1 / 2 (50%) 1 / 2 (50%)
Good 28 / 32 (87.5%) 4 / 32 (12.5%)
Karyotype category 2 Normal 25 / 28 (89.3%) 3 / 28% (10.7%)
Del.5q 3 / 4 (75%) 1 / 4 (25%) 0.0205
Complex 0 / 2 (0%) 2 / 2 (100%)
Trisomy 0 / 1 (0%) 1 / 1 (100%)
Monosomy 1 / 1 (100%) 0 / 1 (0%)
Risk group IPSS-R Very low 10 / 10 (100%) 0 / 10 (0%) o0.0001
Low 16 / 16 (100%) 0 / 16 (0%)
Intermediary 3 / 5 (60%) 2 / 5 (40%)
High 0 / 4 (0%) 4 / 4 (100%)
Very high 0 / 1 (0%) 1 / 1 (100%)
Risk group WPSS Very low 12 / 13 (92.3%) 1 / 13 (7.7%) o0.0001
Low 16 / 17 (94.1%) 1 / 17 (5.9%)
Intermediate 1 / 1 (50%) 1 / 1 (50%)
High 0 / 4 (0%) 4 / 4 (100%)
Risk group IPSS Low 18 / 18 (100%) 0 / 18 (0%) o0.0001
Intermediary 1 11/14 (78.6%) 3 / 14 (21.4%)
Intermediary 2 0 / 1 (0%) 1 / 1 (100%)
High 0 / 3 (0%) 3 / 3 (100%)
WHO 2016 MDS-SLD 5 / 5 (100%) 0 / 5 (0%) 0.0083
MDS-RS 6 / 8 (75%) 2 / 8 (25%)
MDS-MLD 14 / 14 (100%) 0 / 14 (0%)
MDS-EB-1 0 / 1 (0%) 1 / 1 (100%)
MDS-EB-2 1 / 2 (50%) 1 / 2 (50%)
MDS with isolate (5q) 3 / 4 (75%) 1 / 4 (25%)
Evolution to AML 0 / 2 (0%) 2 / 2 (100%)
Transfusion dependence Yes 2 / 7 (28.6%) 5 / 7 (71.6%) 0.001
No 27 / 29 (93.1%) 2 / 29 (6.9%)
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(78.78%, 26/33). Only one patient (33.33%, 1/3), who presen-
ted with a trisomy of chromosome 8, did not respond to high
initial EPO alfa doses (60,000 IU) (Table 1). No statistically
significant association was found between the response to
treatment and the initial dose of EPO alfa (p=0.5412)
Some patients (82.75% 24/29) had a notable and surpris-
ingly prolonged response, ranging from 25 to 175 months.
All of these patients were transfusion independent, and the
majority of these patients were classified by the WHO 2016
and IPSS-R as having a favourable response stratification.
Most patients (87.5%) had blasts p2%. Patients with a
normal karyotype were predominant (83.3%). Only one
patient had a karyotype with monosomy 18 (4.1%), and three
karyotypes showed a 5q- deletion (12.5%). Most patients
(95.8%) also had high platelet levels (X100,000/mm3)
(Table 2).
’ DISCUSSION
Some multicentre studies that assessed the treatment of
MDS patients with EPO reported response rates of approxi-
mately 30-50%, with a duration of 12-24 months (4,5,14,15).
In contrast, the patients from our study centre had a higher
response rate and a longer duration response.
The results of two recent prospective, randomized, placebo-
controlled trials of ESAs in MDS patients with anaemia (16,17)
Table 1 - Continued.
Variable Subgroup Response X2* (p value)
Yes No
Serum erythropoietin (mU/mL)8 o500 10 /12 (83.3%) 2 / 12 (16.7%)
4500 0 / 0 (0%) 0 / 0 (0%)
o200 9 / 10 (90%) 1 / 10 (10%)
4200 0 / 2 (0%) 2 / 2 (100%)
Initial dose EPO alfa UI/week 30,000 27 / 33 (81.8%) 6 / 33 (18.2%) 0.4882
60,000 2 / 3 (66.7%) 1 / 3 (33.3%)
RESPONSE TO TREATMENT WITH EPO ALFA Months Event-free survival (%)
8 83.3
24 80.5
48 80.5
60 80.5
150 80.5
MEAN HAEMOGLOBIN (G/DL) Treatment time (months) mean ± SD
Before 8.89 ± 2.083
p12 10.87 ± 3.063
412-24 12.09 ± 2.220
424-48 11.64 ± 1.766
448-72 10.85 ± 2.472
472-96 12.29 ± 1.708
496-120 12.36 ± 1.168
4120-175 11.35 ± 0.652
Data are n (%) unless indicated otherwise. The relevant cut points were: *hemoglobin values ofo 8 g/dL, 8 -o 10 g/dL, andX10 g/dL; wplatelet values of
o 50  109/L, 50 100  109/L andX 100  109/L, and =absolute neutrophil counts (ANC) ofo 0.8  109/L versusX 0.8  109/L. yCytopenias were defined
as hemoglobin o 11g/dL, absolute neutrophil count o 0.8  109/L or platelets o 100  109/L. 8Not all patients had data available, so percentages are
based on twelve patients (n=12). Abbreviations: World Health Organization 2016 (WHO 2016); International Prognostic Scoring System (IPSS); Revised
International Prognostic Scoring System (IPSS-R); the WHO classification-based Prognostic Scoring System (WPSS); absolute neutrophil count (ANC); and
Standard deviation (SD).
Figure 1 - Overall survival (OS) of the study population treated with epoetin alfa.
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were compared with our data. For example, the ARCADE (16)
study showed a significantly lower incidence of transfu-
sions during treatment in patients receiving darbepoetin
alfa than in those receiving a placebo (p=0.008), and the
darbepoetin-treated patients showed increased erythroid
response rates (14.7%; p=0.016). This erythroid response rate
was comparable to that reported for the EPOANE 3021 trial
(17), where 31.8% of the patients treated with EPO alfa
Figure 3 - The mean haemoglobin of the population studied during treatment with EPO alfa.
Table 2 - Patients with a response of greater than 24 months (25 to 175 months, n=24).
Age Karyotype
IPSS-R
Karyotype Transfusion
dependence
IPSS-R WHO 2016 % Blasts MO Haemoglobin
IPSS-R*
Platelets
IPSS-Rw
Response time
to EPO alfa
(months)
1 64 Good Normal No Very low MDS-MLD p2% Z10 Z100 28
2 95 Good deletion 5q- No Very low MDS with isolated
del 5q-
p2% Z10 Z100 82
3 94 Good Normal No Very low MDS-RS p2% Z10 Z100 145
4 73 Good Normal No Low MDS-MLD p2% o8 Z100 42
5 70 Good Normal No Low MDS-MLD p2% 8-10 Z100 134
6 75 Good deletion 5q- No Low MDS with isolated
del 5q-
p2% o8 Z100 75
7 75 Good Normal No Low MDS-RS p2% 8-10 Z100 30
8 49 Good Normal No Low MDS-MLD p2% 8-10 Z100 66
9 76 Good Normal No Very low MDS-SLD p2% 8-10 Z100 83
10 82 Good Normal No Very low MDS-MLD p2% Z10 Z100 144
11 82 Good Normal No Low MDS-EB-2 5%-10% 8-10 Z100 73
12 65 Good Normal No Very low MDS-MLD p2% Z10 Z100 26
13 74 Good Normal No Low MDS-RS p2% Z10 o50 127
14 65 Good Normal No Very low MDS-MLD p2% Z10 Z100 26
15 70 Good Normal No Intermediary MDS-RS 42% -o5% o8 Z100 175
16 75 Good Normal No Very low MDS-MLD p2% Z10 Z100 88
17 86 Good Normal No Very low MDS-MLD p2% Z10 Z100 65
18 82 Good Deletion 5q- No Very low MDS with isolated
del 5q
p2% Z10 Z100 66
19 68 Good Normal No Low MDS-MLD p2% 8-10 Z100 58
20 73 Good Normal No Intermediary MDS-MLD p2% o8 Z100 66
21 86 Good Normal No Low MDS-MLD 42% -o5% Z10 Z100 35
22 61 Intermediary Monosomy No Low MDS-SLD p2% 8-10 Z100 160
23 80 Good Normal No Low MDS-RS p2% 8-10 Z100 122
24 81 Good Normal No Low MDS-RS p2% 8-10 Z100 98
*Hemoglobin values of o 8 g/dL, 8 - o 10 g/dL and X 10 g/dL; wplatelet values of o 50  109/L, 50-100  109/L and X 100  109/L; yCytopenias were
defined as hemoglobino 11g/dL; absolute neutrophil counto 0.8  109/L; or plateletso 100  109/L. Abbreviations: Revised International Prognostic
Scoring System (IPSS-R); World Health Organization 2016 (WHO 2016); MDS with multidrug dysplasia (MDS-MLD), MDS with ringed sideroblasts (MDS-RS),
MDS with dysplasia (MDS-SLD), MDS with excess blasts 2 (MDS-EB-2), and MDS with del (5q) isolated.
6
Prolonged response to epoetin alfa in MDS
Moura ATG et al.
CLINICS 2019;74:e771
reached the target response erythroid level, whereas 4.4% of
the placebo-treated patients reached the target response level
(po0.001). In our study, none of the transfusion-independent
patients required transfusions during treatment with EPO,
and transfusion dependence was also reduced. These results
are particularly significant for everyday clinical practice,
where the goal in the management of patients with low-risk
MDS is to achieve transfusion independence, as transfusion
independence is associated with improved survival (18). Our
sustained rates of erythroid response following the initiation
of EPO alfa treatment may also reflect the need for prolonged
treatment to obtain the full clinical benefit.
Another interesting finding was related to the incidence of
elevated haemoglobin levels, which was lower than expected
in the EPOANE 3021 and ARCADE studies. The suggested
cause for this result was that a dose adjustment above the
initial low-dose regimen was allowed only after 8 weeks in
the EPOANE 3021 study and after 31 weeks in the ARCADE
study. In addition, a higher response rate was observed in
patients treated with higher doses of ESAs (80,000 IU/week).
Other studies on ESA treatments have reported the use of
significantly higher doses of EPO alfa, ranging from 40,000-
80,000 IU/week, in patients with MDS than in patients with
other clinical indications, as higher dosing is thought to aid
in counteracting the intrinsic resistance of MDS erythroid
precursors to EPO alfa (19,20,21). In the present study, the
administered dose range was 30,000-60,000 IU/week (22),
and dose adjustments were based on the patient haemoglo-
bin levels (a reduction or increase of 1.5 g/dL of haemo-
globin in 30 days in the absence/presence of erythrocyte
transfusions) and clinical status. Doses were adjusted for
97.22% (35/36) of the patients. In patients with MDS, when a
positive response is obtained, ESA doses can be adjusted to
the lowest effective dose that maintains haemoglobin levels
within the normal range. Thus, a high percentage of patients
with low-risk MDS will respond to treatment with EPO alfa
and have higher response rates (23).
Another noteworthy observation was that no patients
received hypomethylating agents (azacitidine or decitabine)
and lenalidomide in addition to EPO alfa. Some studies have
suggested that erythroid response rates can be increased
with this type of combination therapy (24,25).
High-risk stratifications and transfusion dependence had a
negative impact on event-free survival in the patients in this
study and could be considered predictors of a poor response
to EPO alfa treatment. These findings agree with previous
studies that observed lower rates and shorter durations of
the response to EPO treatment in patients at high risk and
with transfusion dependence (26).
The WHO stratification is an important tool for determin-
ing the most appropriate therapeutic management for each
patient. Published studies have shown that MDS-RS, MDS-
EB, and del (5q) patients have a better response to ESA
therapy, whereas the MDS-SLD and MDS-MLD groups
have a worse response, regardless of transfusion dependence.
Not much evidence is available and published on this topic,
but patients with a 5q chromosomal abnormality seem to
respond with a significantly lower response rate to both the
EPO alfa and darbepoetin isoforms (with or without G-CSF)
than MDS patients without a 5q deletion (27). This finding is
in agreement with our data, which also revealed a low
response rate to EPO alfa in subjects with a 5q deletion.
Although three patients with 5q deletions presented pro-
longed responses, the response rates were low.
The characteristics of the patients who had significantly
longer responses to treatment (25 to 154 months) confirmed
the favourable prognosis and response of patients in the low-
risk categories, which are characterized by no transfusion
dependence, a normal karyotype, and a small number of
bone marrow blasts (28). In patients with MDS, prognosis
was better in those with a normal karyotype than in those
with the presence of any structural or numerical changes.
The karyotype also plays an important role in establishing
the MDS diagnosis because during the course of the disease,
cytogenetic methods are used to assess the response to
therapy or to examine clonal evolution, which is a sign of
disease progression (29).
Among the patients who did not respond to treatment, the
predominant features included a complex karyotype, tris-
omy 8 and transfusion dependence. Patients with a complex
karyotype showed an accumulation of progressive changes
and greater disease aggressiveness, which were associated
with an extremely unfavourable prognosis and a high pro-
pensity to transform into acute leukaemia within a short period
of time. This observation was confirmed as a statistically
significant association in our study (p=0.01), thereby demon-
strating the importance of cytogenetic studies in the evolu-
tionary monitoring of MDS. Patients with trisomy 8, as an
isolated anomaly, have a significantly higher risk of leukaemic
transformation than other patients, but the significance of the
gain of an extra chromosome 8 is not yet fully understood
(29,30).
In recent years, the value of serum erythropoietin in MDS
has been explored in the literature as a predictor of the
response to EPO. The role of sEPO levels as a prognostic risk
factor in MDS also remains poorly understood. Despite
the benefits of growth factor therapy, and of erythropoi-
etin therapy in particular, studies have shown that sEPO levels
(o500 IU/L) are predictive of response (9,10,11). Patients who
present with low sEPO levels associated with anaemia before
treatment appear to respond more readily to EPO. These
observations are further supported by the findings of other
EPO studies (14,31). We observed a response in greater than
80% of patients with low sEPO levels. A limitation of the
present study was the number of patients and the lack
of availability of data on the sEPO levels in all patients;
however, this examination is not covered by the Brazilian
Unified Health System (SUS).
The results obtained in the present study support the
importance of EPO alfa treatment for patients with MDS
and suggest that the use of EPO alfa might achieve durable
responses, thereby guaranteeing an improvement in the
quality of life of these patients. However, the evaluation
of each patient’s clinical characteristics, such as their risk
stratification and transfusion dependence, is essential prior
to the initiation of EPO alfa treatment.
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